Forsante has more than ten years of strong evidence in the guidance of complex medication therapies. This long-standing experience has also formed the foundation for the development of the IRMA decision support module.
The same principles that have enabled Forsante to achieve excellent results in the automated management of warfarin therapy are now being extended to other cardiometabolic treatment areas, including the management of hypertension, lipid disorders, and type 2 diabetes care.
Post-market clinical follow-up of Forsante Anticoagulation, which has been in use for over ten years (an MDD Class IIb dosing module), has demonstrated the effectiveness of automated medication management:
Among patients treated with Forsante Anticoagulation, the median time spent within the therapeutic range (Time in Therapeutic Range, TTR) was 83%, and the mean TTR was 79.2%—clearly exceeding the 70% benchmark for high-quality anticoagulation therapy.
With Forsante’s dosing recommendations, target INR levels were achieved 50% more often than with manually determined dosing (p < 0.001).
No misleading dosing recommendations were reported. The rare cases in which a dosing recommendation was missing were due to issues related to external data integration, not system errors.
The safety profile of Forsante Anticoagulation remains well within acceptable limits, and no critical risks have been identified.
The automation of warfarin therapy management by Forsante demonstrates the capability on which the more versatile Forsante IRMA has been built. By integrating IRMA into clinical workflows, healthcare professionals can deliver safer, more consistent, and more personalized care across the entire spectrum of chronic disease management.
Learn more about Forsante IRMA
